The British Medical Association has reversed course. The union that once voted to call the Cass Review's findings "unsubstantiated" published its own internal review and declared the methodology robust, withdrawing its opposition to all 32 of Dr Hilary Cass's recommendations. I read that sentence several times. The body that had been one of the few institutional voices willing to push back has now, quietly, stepped aside.

The Cass Review is internationally discredited. Researchers and clinicians across Europe and beyond have examined its methodology, its evidence base, the way it handled systematic reviews, and the sources it drew on, and they have found it wanting. Gender experts have published detailed rebuttals. The professional bodies whose endorsement matters most in global gender medicine have not followed its lead. That position has not changed because the BMA has changed its mind. One institution's internal review, conducted by 12 of its own members, does not alter the international picture.

What it does alter is the political landscape here at home, and that matters enormously to real people.

What the BMA actually said

The BMA's review, led by Prof David Strain, chair of its board of science, concluded that Cass's methodology was sound and that the union would no longer oppose any of the 32 recommendations. Strain acknowledged that "interpretations and policy preferences" within the group had diverged, which is a polite way of saying this was not a unanimous or uncomplicated conclusion. He also acknowledged the ongoing challenge of managing uncertainty in gender care, which is fair enough, but managing uncertainty is something medicine does in every speciality, every day. It is not a reason unique to gender care to withdraw treatment, close services, or wait four years before publishing a review of a review.

Despite largely vindicating Cass, the union maintained its opposition to the puberty blocker ban, on the grounds that a political decision affecting how doctors prescribe undermines clinical autonomy. "We spend decades training on how to use drugs," they said, "and to have a political decision affecting the way we prescribe is wrong." That is correct, and I am glad they said it. The ban on puberty blockers went beyond what Cass herself recommended, and the BMA is right to resist it on those terms. Doctors should be able to prescribe medicines based on clinical evidence and individual patient need, not because a government has decided to restrict an entire class of drugs for a specific group of young people.

The people this is actually about

The Tavistock's gender identity development service closed permanently in March 2024. It had treated around 9,000 children and young people over more than a decade, with an average referral age of 14. In its place, new regional hubs were promised. The waiting lists did not disappear when the service did; they moved. Young people who had been referred, assessed, and were waiting for the next step found themselves back at the beginning. Families who had spent years navigating a system that was already barely functioning watched it close.

Those are the people I think about when I read news like this. Not the institutional manoeuvres, not the policy language, not the carefully worded statements about "ethical complexity." The 14-year-old who has been waiting three years. The parent who has watched their child's distress deepen while the adults argued about methodology. The young person who turned 18 mid-wait and had to start the adult pathway from scratch.

Delay is not neutral. I have said this before and I will keep saying it. Every month a young person waits for care that could reduce their distress is a month of an unwanted puberty, of compounding dysphoria, of isolation and suffering. The argument that we need more evidence before acting was always a choice with consequences, and those consequences fell on specific young people, not on the committees debating their care.

What institutional courage looks like, and what its absence costs

When the BMA's council voted to oppose Cass's implementation and called its findings unsubstantiated, that was an act of professional courage. It was a major body saying: we have looked at this, and we do not think the evidence meets the bar you are claiming it meets. It gave families, clinicians, and advocates something solid to point to. It said: you are not imagining this, the professional establishment is not unified behind the review.

That signal has now been withdrawn. The BMA's reversal does not mean the evidence has improved. It means the political pressure has been sustained long enough, and consistently enough, that maintaining the opposition became harder than finding a form of words that stepped back from it while preserving a little dignity on the puberty blocker question. That is my read, and I acknowledge it is a reading rather than a certainty.

What I am certain of is this: the trans young people still waiting, still living with untreated dysphoria, still watching the system fail them, are in a more isolated institutional position today than they were before Wednesday. One fewer voice in their corner is one fewer voice in their corner, whatever language surrounds the retreat.

The Cass Review's international discrediting did not begin when the BMA first opposed it, and it does not end now that the BMA has stopped. The evidence is the evidence. But institutions matter, and the BMA's decision to step back matters to the people whose lives this shapes.

I hope the BMA's continued resistance to the puberty blocker ban is sustained, and that the clinicians within it who understand the harm of delay keep making that case loudly. The young people waiting deserve no less.

If there is a news story you would like me to cover then just let Sammy know.

Dr Helen Webberley is a Gender Specialist, Medical Educator, and founder of GenderGP. She writes about gender identity, trans healthcare, and the lives at the centre of both.